‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

Aldosterone Inhibitors Poised To Revolutionize Hypertension Treatment

 
• By Sushmita Panda
  
Jon Congleton, Chief Executive Officer (CEO), Mineralys Therapeutics
Jon Congleton, Chief Executive Officer, Mineralys Therapeutics (Mineralys Therapeutics)
In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Leadership

More from In Vivo